Table 1 Analyzed sequences from common fragile site regions and number of MLV integrations in each fragile region
From: Erratum: Fragile sites are preferential targets for integrations of MLV vectors in gene therapy
Chromosomal positiona | First DNA markerb | Last DNA markerb | Referencee | CD3+c | HeLad | |
|---|---|---|---|---|---|---|
FRA2G | chr2: 169,452,095- 170,292,618 | RH91148 | RH1293 | 5 | 1 | 1 |
FRA3B | chr3: 59,594,241- 64,182,258 | D3S3577 | D3S1287 | 6 | 1 | |
FRA4F | chr4: 89,694,006- 97,605,145 | RH94252 | D4S2407 | 7 | 1 | 3 |
FRA6E | chr6: 160,551,547- 163,760,142 | RH92608 | RH63999 | 8 | 2 | |
FRA6F | Chr6: 106,922,988-112,526,158 | SHGC-140029 | D6S1259 | 9,10 | 1 | 1 |
FRA7E | chr7: 79,882,815-84,580,600 | swss4015 | SHGC-104456 | 11 | 6 | |
FRA7G | chr7: 109,809,464- 116,030,383 | RH122988 | D7S2863 | 12,13 | 2 | |
FRA7H | chr7: 129,368,585-130,393,035 | A006N09 | D7S2531 | 2 | 2 | 1 |
FRA7I | chr7: 144,322,489-145,530,291 | D7S1477 | D7S739 | 14 | ||
FRA8C | chr8: 124,267,550-128,310,523 | D8S1160 | SHGC-130454 | 13 | 2 | |
FRA9E | chr9: 106,403,642-116,118,637 | SHGC-106699 | RH62868 | 15 | 3 | 2 |
FRA11E | chr11: 31,953,729 -33,948,551 | D11S1964 | D11S4965 | This study | 5 | 2 |
FRA16D | chr16: 76,161,223-77,681,818 | D16S3138 | D16S516 | 16,17 | ||
FRAXB | chrX: 6,827,880- 7,285,010 | DXS1130 | DXS1133 | 18 | ||
15 | 21 |
